Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24123490 | 0.91 | F2RL3 (0.38) | F2RL3FFAR4FFAR1ABCB1CTSL | |
| SCHEMBL24123680 | 0.73 | P2RX7 (0.31) | — | |
| SCHEMBL24123651 | 0.69 | HTR2A (0.35) | FFAR4 | |
| SCHEMBL2550366 | 0.62 | FFAR4 (0.49) | FFAR4FFAR1ABCB1KEAP1NFE2L2 | |
| SCHEMBL24075154 | 0.62 | P2RX7 (0.30) | — | |
| SCHEMBL28921334 | 0.62 | MAOB (0.51) | FFAR4FFAR1ABCB1KEAP1NFE2L2 | |
| SCHEMBL22070810 | 0.61 | LTA4H (0.46) | FFAR1ABCB1KEAP1NFE2L2 | |
| SCHEMBL22070546 | 0.60 | LTA4H (0.48) | FFAR1ABCB1 | |
| SCHEMBL14700006 | 0.60 | APP (0.47) | ABCB1NPC1RAB9A | |
| SCHEMBL21988922 | 0.60 | NPC1 (0.53) | KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234969-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234969-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-27 | — | — | US | disclosed |
| WO-2021255257-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234969-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | MCL1, BAK1, BCL2L1 | F2RL3 4223/4885KMT2A 2162/4885FFAR4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.